Niraparib sustained and controlled release pharmaceutical composition and use thereof
AssigneeScience Rainbow Biopharma Co. Ltd
InventorsYong Gan, Bingxue Meng, Yan Liu, Chunliu Zhu, Shiyan Guo
Life of this patent
Estimating the term…
Abstract
Provided are a niraparib sustained and controlled release pharmaceutical composition and use thereof. The sustained and controlled release pharmaceutical composition contains dissolution-improved niraparib and a matrix polymer used for regulating release rate; the steady-state plasma concentration trough value Cmin,ss of the pharmaceutical composition is 0.5-4 μM; the steady-state plasma concentration peak value Cmax,ss is 0.8-6 μM.
Claims10
A niraparib sustained and controlled release pharmaceutical composition, comprising a niraparib in an improved dissolution form and a matrix polymer for adjusting release rate;
- the niraparib sustained and controlled release pharmaceutical composition has a steady-state blood concentration trough value Cmin,ss of 0.5-4 μM;
- a steady-state blood concentration peak value Cmax,ss of 0.8-6 μM.
Dependencies are inferred from the claim text.